Archive — US — techcrunch
Ready-made stem cell therapies for pets could be coming
San Diego startup Gallant secured $18 million funding for FDA-approved ready-to-use stem cell therapies for pets, targeting Feline Chronic Gingivostomatitis first. Effective treatments for various conditions in pets may revolutionize veterinary medicine, with potential FDA approval by early 2026.
Key points
- Gallant announced $18 million funding to develop stem cell therapy for pets.
- Target condition is Feline Chronic Gingivostomatitis (FCGS) in cats.
- If successful, this therapy may receive FDA approval by early 2026.
- Current stem cell treatments require harvesting from patients, Gallant's is ready-to-use.
- Initial studies have shown benefits in dogs with arthritis, but mixed results in cats.
- Gallant has raised a total of $44 million from various investors.
Why it matters
- Veterinary stem cell therapy is an emerging field, paralleling human stem cell advancements.
- 2025 IT trends show increasing investment in biotech, especially in regenerative medicine.
- The rise of personalized medicine is influencing both human and veterinary care development.
Gallant's initiative marks a significant stride towards innovative veterinary care by leveraging advancements in stem cell therapy, potentially improving treatment options for pets and changing the industry landscape.